Finance

Lists
TEVA:NYSE
Teva Pharmaceutical Industries Limited
41,52 USD
+1,01%
(+0,42) 1D
16-окт., 15:50:23 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TEVA...
Open
41,26 USD
High
41,70 USD
Low
40,96 USD
Mkt. cap
47,60 млд
Avg. vol.
5,93 млн
Volume
4,44 млн
52-wk high
42,02 USD
52-wk low
18,82 USD
Beta
1,07
Shares outstanding
1,17 млд
No. of employees
32 миң
Open
41,26 USD
High
41,70 USD
Low
40,96 USD
Mkt. cap
47,60 млд
Avg. vol.
5,93 млн
Volume
4,44 млн
52-wk high
42,02 USD
52-wk low
18,82 USD
Beta
1,07
Shares outstanding
1,17 млд
No. of employees
32 миң
News stories
From web sources and news partners
Profile
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients and, to a lesser extent, contract manufacturing services and an out-licensing platform. Teva's primary branded products include Austedo which is used for the treatment of chorea associated with Huntington's disease and tardive dyskinesia; and Ajovy, used for the preventive treatment of migraine in adults. Additional branded drugs sold by Teva include Copaxone, Bendeka and Treanda, all of which are primarily sold in the United States. Teva is listed on the Tel Aviv Stock Exchange and the New York Stock Exchange. Its manufacturing facilities are located in Israel, North America, Europe, Australia, and South America. The company is a member of the Pharmaceutical Research and Manufacturers of America. Teva Pharmaceuticals is the largest generic drug manufacturer in the world. Overall, Teva is the 26th largest pharmaceutical company in the world. Teva has a history of legal trouble in relation to collusion and price-fixing to inflate prices for drugs. Wikipedia
About Teva Pharmaceutical Industries Limited
CEORichard Francis
Employees32 миң
Founded1944-ж., 13-фев.
Headquarters-
SectorPharmaceutical industry
Websiteteva.co.il
Analyst ratings
Based on 9 analysts giving stock ratings to TEVA in the past 3 months
Strong buy
Buy
9
Hold
0
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for TEVA in the last 3 months.
Highest
Current 41,52 USD
50,00 USD (+20,41%)
Average
44,00 USD (+5,96%)
Lowest
40,00 USD (-3,67%)
Analyst
Recommendation
Action
Price target
Projected
Date
Daniel Clark
Leerink Partners
Buy
Initiated
45,00 USD
+8,4%
09/09/2026
Ashwani Verma
UBS
Buy
Maintained
48,00 USD
+15,6%
09/04/2026
Dennis Ding
Jefferies
Buy
Maintained
40,00 USD
-3,7%
09/03/2026
Louise Chen
Scotiabank
Buy
Maintained
40,00 USD
-3,7%
09/03/2026
Salveen Richter
Goldman Sachs
Buy
Maintained
50,00 USD
+20,4%
09/02/2026
Jason Gerberry
Bank of America Securities
Buy
Reiterated
43,00 USD
+3,6%
09/02/2026
Umer Raffat
Evercore ISI
Buy
Maintained
-
-
09/02/2026
David Amsellem
Piper Sandler
Buy
Reiterated
44,00 USD
+6%
08/27/2026
Glen Santangelo
Barclays
Buy
Maintained
42,00 USD
+1,1%
08/12/2026
Chris Schott
J.P. Morgan
Buy
Maintained
-
-
06/15/2026
Matthew Dellatorre
Goldman Sachs
Buy
Maintained
50,00 USD
+20,4%
04/30/2026
Les Sulewski
Truist Financial
Buy
Reiterated
45,00 USD
+8,4%
04/30/2026
Last report
2026-ж., 29-июл.
Fiscal period
Q2 2026
0,02 USD / 0,11 USD
-81,46%miss
Revenue / Est. (USD)
4,14 млд / 4,03 млд
+2,79%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
4,48 млд
4,71 млд
3,98 млд
4,14 млд
Cost of goods sold
2,18 млд
2,06 млд
2,01 млд
1,99 млд
Cost of revenue
2,18 млд
2,06 млд
2,01 млд
1,99 млд
Research and development expenses
256,00 млн
267,00 млн
222,00 млн
970,00 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
973,00 млн
1,12 млд
1,00 млд
1,03 млд
Operating expense
1,24 млд
1,37 млд
1,21 млд
1,99 млд
Total operating expenses
3,41 млд
3,43 млд
3,22 млд
3,98 млд
Operating income
1,07 млд
1,28 млд
763,00 млн
167,00 млн
Other non operating income
-27,00 млн
-
-13,00 млн
-69,00 млн
EBT including unusual items
648,00 млн
90,00 млн
436,00 млн
-455,00 млн
EBT excluding unusual items
832,00 млн
1,08 млд
547,00 млн
-57,00 млн
Income tax expense
214,00 млн
-390,00 млн
67,00 млн
121,00 млн
Effective tax rate
33,02%
-433,33%
15,37%
-26,59%
Other operating expenses
9,00 млн
-17,00 млн
-14,00 млн
-18,00 млн
Net income
433,00 млн
480,00 млн
369,00 млн
-576,00 млн
Net profit margin
9,67%
10,19%
9,27%
-13,91%
Earnings per share
0,78
0,96
0,53
0,02
Interest and investment income
-
92,00 млн
-
-
Interest expense
-205,00 млн
-280,00 млн
-191,00 млн
-186,00 млн
Net interest expenses
-205,00 млн
-188,00 млн
-191,00 млн
-186,00 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
1,32 млд
1,54 млд
1,00 млд
408,00 млн
Gain or loss from assets sale
-
-
-8,00 млн
-12,00 млн
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google колдонмолору